Manhattan BioSolutions, Inc.

The Manhattan BioSolutions, Inc. team was honored to attend an exclusive event organized by SternAegis Ventures & Aegis Capital Corp. at the RT60 Rooftop Bar & Lounge, located on the 34th floor of the Hard Rock Hotel New York. This invitation-only reception brought together top professionals from the biotech, finance, and investment communities in the heart of Times Square. #biotech #innovation Borys S. Jenny Maharjan, MBA, B.Pharm John Psaltos William Johnson G. JOHN MOHR

Manhattan BioSolutions, Inc. had an incredible experience at the 2024 JLABS Investor & Partnering Day, held at the New York Genome Center, home of JLABS@NYC. This expertly curated event brought together innovative biotech startups and investors from the US North East region. A special thanks to the Johnson & Johnson Innovation JLABS team, including Scott Shepherd, Miriam Huber, Tingting Zhang-Kharas, PhD, and Jesse Hwang, for their tireless efforts in creating this impactful event. The expert speakers, including Marian Nakada, Ph.D., Katie Bodner Spielberg, Rachel Mears, and Pablo Lubroth, offered invaluable guidance on navigating the current fundraising environment. It was great to reconnect with Michal Preminger, Head of Innovation, East North America, Sharon Chan, VP of JLABS Asia Pacific, and Jun X., Executive Director - Therapy Acceleration Program Lead, The Leukemia & Lymphoma Society, after the event. We invite investors and collaborators to explore partnership opportunities with us as we work towards groundbreaking solutions in the biotech space. Thank you JLABS, for empowering the biotech startup ecosystem and facilitating meaningful connections that will shape the future of healthcare. (Pictured: Borys S. and Jenny Maharjan, MBA, B.Pharm from the Manhattan BioSolutions, Inc., team) #JLABS #biotech #innovation

We are thrilled to share that a U.S. patent application has been filed for a potent antibody-drug conjugate (ADC) therapy, marking a significant milestone in our ongoing collaboration with the National Cancer Institute (NCI) and Binghamton University. This filing builds upon the promising preclinical data generated through our joint efforts and aims to provide a novel and effective treatment option for patients with cancers that express high levels of the target receptor, such as rhabdomyosarcoma and certain breast and liver cancers. By combining novel antibodies with innovative tumor-cleavable linker-payload technology, we are working to create a new class of targeted therapies that can selectively deliver potent anti-cancer agents directly to tumor cells while minimizing toxicity to healthy tissues. For investor inquiries, please contact: Borys S. or John Psaltos. #innovation #fightcancer #biotech.

Manhattan BioSolutions is proud to announce a collaborative poster presentation at #AACR2024 showcasing our work with the National Cancer Institute (NCI) and Binghamton University on a novel FGFR4-targeted antibody-drug conjugate (ADC) for the treatment of rhabdomyosarcoma and other tumor types. The poster highlights the promising preclinical efficacy of this innovative therapeutic approach, which utilizes a highly specific monoclonal antibody conjugated to a cytotoxic payload. We are excited to continue our work with cutting-edge linker-payload technologies to further enhance the potential of the ADCs for treating various types of cancers and addressing unmet medical needs. We would like to express our gratitude to our collaborators, lead investigator Javed Khan and L. Nathan Tumey, as well as the dedicated members of their labs who were involved in this work. https://lnkd.in/eveymTC6 https://lnkd.in/ev2UQHaS #ADC #biotech #innovation #cancer

We are pleased to share the latest research publication from our scientific advisor, Dhaval Shah, and his team at the University at Buffalo. In this comprehensive study, Dr. Shah and colleagues developed a groundbreaking generalized pharmacokinetic (PK) model for monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs). Through a rigorous analysis of clinical PK data from 18 different MMAE-based ADCs, Dr. Shah's team demonstrated the generalizability of PK profiles across various targets, indications, dosing regimens, and average drug-antibody ratios (DARs). This remarkable finding enabled them to develop a novel PK model that can simultaneously capture the PK of all four ADC analytes commonly measured in clinics: total antibody, conjugated antibody (ADC), conjugated MMAE, and unconjugated MMAE. The generalized PK model serves as an invaluable tool for a priori predicting the clinical PK of MMAE-based ADCs across different doses. It also lays the foundation for establishing generalized exposure-response and exposure-toxicity correlations, which are crucial for therapeutic optimization. This pioneering research has significant implications for accelerating the clinical development and optimization of MMAE-based ADCs, a promising class of immunotherapies in oncology and beyond. The findings will likely shape future strategies for exposure-response analyses and dose selection for these ADCs. We are proud to have Dr. Shah as our scientific advisor at Manhattan BioSolutions, Inc., where we are actively working on developing next-generation ADC approaches. Congratulations to Dr. Shah and his team on this achievement! #ADC #biotech #innovation https://lnkd.in/ezZq7bY9

Manhattan BioSolutions, Inc. would like to extend our heartfelt gratitude to Scorpius BioManufacturing, Inc. Jeff Wolf Kristofer Morton and the DCAT (Drug, Chemical & Associated Technologies Association) for inviting us to the 96th DCAT Annual Dinner. It was an incredible evening of networking and learning alongside professionals in the bio/pharmaceutical manufacturing industry. We were thrilled to hear from the event's guest speaker, seven-time World Champion Tom Brady (Tom Brady), who shared valuable insights from his remarkable career both on and off the field. His words on the pursuit of excellence and the importance of philanthropy were truly inspiring. Special thanks to the hosts of the post-dinner events hosted by esteemed DCAT Member Companies, including Amcor Flexibles, Asymchem Group Inc., Lonza AG, Resilience, Siegfried, Takasago International Corporation , Thermo Fisher Scientific, and WuXi Chemistry (WuXi STA & WuXi TIDES) Their commitment to fostering connections and collaboration within the industry is greatly appreciated #biotech #innovation #NYC #biologics #ADC

Our team attended the "Breakthroughs in Precision Oncology: A Therapeutic Frontier" event at JLABS NYC . Hosted in partnership with the Cancer Research Institute (CRI), this event brought together experts in precision oncology to discuss advancements and future directions in personalized cancer treatment. Dr. Scott W. Lowe's provided insights into understanding and exploiting senescence biology in cancer and beyond. The panel discussion, moderated by Tingting Zhang-Kharas, PhD, Head of JLABS US Northeast, featured oncology experts from the Cancer Research Institute, Albert Einstein College of Medicine, Mount Sinai, and MSKCC: Scott W. Lowe Jay Campbell Nancy Ondovik Joshua Brody, MD Xingxing Zang, who shared their perspectives on the current state and future potential of precision oncology. We enjoyed engaging in discussions during the Q&A session and connecting with innovators at the networking reception organized by NewYorkBIO. Manhattan BioSolutions, Inc. BioSolutions is committed to advancing precision oncology and developing solutions to improve patient outcomes. We thank Johnson & Johnson Innovation JLABS for hosting this impactful event and promoting collaborations within the life sciences community. Together, we can revolutionize cancer treatment through precision oncology. #PrecisionOncology #CancerResearch #Innovation #JLABS #biotech

Manhattan BioSolutions, Inc. enjoyed celebrating International Women's Day with the fantastic community at Johnson & Johnson JLABS NYC yesterday! We're proud to be a part of this supportive environment that recognizes the achievements of women in science and entrepreneurship. 🧪🔬. We appreciate the brilliant and passionate women on our advisory board who bring their expertise and insights to drive our company forward. Your dedication inspires us every day. 👩🏽🔬💪🏼 Thanks for a great event, JLABS and Tingting Zhang-Kharas, PhD ! 😊 #WomenInScience #IWD2024 #WomenInSTEM #Innovation #Diversity #Empowerment

We are pleased to announce that the team from Manhattan BioSolutions, Inc. will be attending the 10th Annual Immuno-Oncology 360° Summit (#IO360) in Brooklyn, NY from February 26-28. This premier event offers an invaluable opportunity for us to connect with scientists, KOLs and industry leaders working on the most innovative cancer immunotherapies. During the summit, we welcome the opportunity to showcase our proprietary precision biologic platforms: RNA-degraders and ADC therapies. Our ADC approaches can enable targeted delivery of immuno-oncology agents such as TLR7 agonists to tumors resulting in greater anti-tumor activity and improved safety compared to systemic administration. Looking forward to hearing from keynote and featured speakers: Drs Patrick Hwu Laura Esserman Taha Merghoub Andrew Baum Ira Mellman Margaret Callahan Kristen Hege Jason Luke Alexandra Snyder, MD Rajiv Kaul . If you'll be attending, we welcome the chance to discuss win-win licensing opportunities, potential collaborations, or investment interest with aligned stakeholders who share our commitment to progressing breakthrough immuno-oncology therapies. Learn more about our precision biologics: https://lnkd.in/eHr67KG2. See you at #IO360! #biotech #innovation Immuno-Oncology 360° Community News

Our team Manhattan BioSolutions, Inc. is thrilled to be attending this Friday's (February 23rd) Biocytogen exclusive Symposium on novel targets and therapeutics in Waltham, MA. We were excited to see Biocytogen announce their new multi-target antibody collaboration with Gilead Sciences earlier this week. This major deal provides further validation of Biocytogen’s powerful RENMICE® platforms for fully human antibody discovery. We also recognized this potential when we signed our own antibody evaluation agreement with Biocytogen in January. We look forward to hearing insights from distinguished researchers Dr. Dan Littman of NYU, Dr. Gordon Freeman of Dana-Farber Cancer Institute, Dr. Nimish Gera, VP of Biologics Mythic Therapeutics, Inc. , Dr. Virna Cortez-Retamozo, Distinguished Scientist, Onco-Pharmacology at Sanofi US and Dr. Yuelei Shen, Founder, President & CEO of Biocytogen, on their new fully human antibody library. The symposium will also provide a valuable opportunity for networking to discuss potential new R&D collaborations and partnerships in these areas. If any of our connections are attending as well, we would enjoy meeting up. #cancer #ADCs #innovation